Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma
After years of research, many exciting and effective new combination treatments exist for patients with advanced melanoma. As a result, patients and their physicians often find themselves with multiple treatment options but few answers to questions surrounding how and when to use these new approaches. In addition, melanoma can be highly aggressive, and existing treatments often stop working. Final results are now available for the randomized phase 3 trial DREAMseq (EA6134) for melanoma patients with a BRAF V600 tumor gene mutation.
DREAMseq showed that starting treatment with immunotherapy (nivolumab and ipilimumab), followed by targeted therapy (dabrafenib and trametinib) if there is disease progression, is the preferred treatment approach. “I think the standard of care should immediately change because these are FDA-approved regimens,” said lead researcher Michael B. Atkins, MD (Georgetown University Lombardy Comprehensive Cancer Center). Atkins MD. J Clin Oncol. September 2022
###
Related Posts
Lung-MAP Shows Potential of Public-Private Partnerships
Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research
Bladder Cancer Subtype Association with Response
RNA-based molecular subtypes modestly improved predictions for pathologic downstaging in muscle-invasive bladder cancer.
Lung-MAP Broadens Trial Access for Some Groups
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung-MAP trial has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance